Assyro AI

FDA Orange Book · active-ingredient family

Loratadine; pseudoephedrine sulfate

Loratadine; pseudoephedrine sulfate is approved as 2 brand and 6 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:CLARITIN-D · NDA 019670

2

Brand (NDA)

6

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · tablet, extended release

ProductApplicantApplicationTEApproved
CLARITIN-DRLDBAYER HEALTHCARE LLCNDA 019670Nov 27, 2002
CLARITIN-D 24 HOURRLDBAYER HEALTHCARE LLCNDA 020470Nov 27, 2002

Generic (ANDA) products (6)

ProductApplicantApplicationTEApproved
LORATADINE AND PSEUDOEPHEDRINE SULFATEBIONPHARMAANDA 218017May 14, 2024
LORATADINE AND PSEUDOEPHEDRINE SULFATESUN PHARM INDS LTDANDA 076557Sep 22, 2004
LORATADINE AND PSEUDOEPHEDRINE SULFATEPERRIGO PHARMA INTLANDA 075989Mar 04, 2004
LORATADINE AND PSEUDOEPHEDRINE SULFATEHERITAGE PHARMAANDA 076208Jan 28, 2004
LORATADINE AND PSEUDOEPHEDRINE SULFATEP AND LANDA 075706Feb 21, 2003
LORATADINE AND PSEUDOEPHEDRINE SULFATEPERRIGO PHARMA INTLANDA 076050Jan 30, 2003

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Loratadine; pseudoephedrine sulfate — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.